Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the clinical efficacy of non-invasive ventilation (NIV) in treating patients with high-altitude polycythemia (HAPC).
Participants will be enrolled according to the international diagnostic criteria for high-altitude polycythemia. The study will use both retrospective cohort and prospective study methods.
All participants will receive standard basic care. In addition, the intervention group will receive non-invasive ventilation treatment using either BiPAP or CPAP mode.
Key measurements, including routine blood tests, liver function, renal function, uric acid, blood lipid profile, electrocardiogram and echocardiography, will be collected as primary and secondary outcome measures to assess the effects of the treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention Group (NIV Treatment) | Experimental | Patients receive standard basic care plus long-term non-invasive ventilation (NIV) therapy with CPAP or BiPAP mode. Treatment is administered daily, and efficacy is evaluated 3 to 6 months after the intervention. |
|
| Control Group (Standard Care Only) | No Intervention | Patients receive only standard basic care without non-invasive ventilation therapy. Efficacy is evaluated at the same time points (3 and 6 months) as the intervention group for comparison. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-invasive ventilator | Other | Treatment with non-invasive ventilator (CPAP, BiPAP) in the intervention group. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Hemoglobin (Hb) Concentration | The primary endpoint is the absolute change in blood hemoglobin concentration (g/dL) from baseline to 3-month and 6-month follow-up. A reduction in hemoglobin level is defined as a clinically significant improvement in high altitude polycythemia status. | Baseline, 3 months, 6 months after treatment initiation |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Serum uric acid and blood lipid levels | Changes in serum uric acid, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) will be measured. | Baseline, 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gesang Luobu, MD | Contact | 8618108912487 | kelsangnorbu@hotmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| People's Hospital of Xizang Autonomous Region;Lhasa, Xizang Autonomous Region, China, 850000 | Xizang | China | ||||
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Xizang Autonomous Region People's Hospital |
| Xizang |
| China |
|